THE CHALLENGES OF CHRONIC ANTICOAGULATION IN PATIENTS WITH PROSTHETIC HEART VALVES
Main Article Content
Abstract
The vitamin K antagonists (VKA) had been the sole option to reduce or prevent the mechanical prosthetic valve thrombosis and thromboembolic phenomena for last several decades. Their chronic usage can lead to both bleeding as well as thrombotic complications. As the therapeutic window for the drug levels is very narrow, VKA therapy needs close monitoring and periodic blood testing (PT-INR). Patients have to follow bothersome diet restrictions. Patient-education and co-operation are paramount for maintaining the INR in the prescribed safe range. The recommendation for bridging therapy when the patients with mechanical valves are subjected to any procedure or surgery is not standardized and such instructions are often confusing to patients, family members and ill-trained health professionals. The management of special populations such as the pregnant and the elderly continue to be very challenging. Anticoagulation is generally avoided in those with bioprosthetic valves unless there is atrial fibrillation. An early clinical trial with rivaroxaban in patients with bioprosthetic valves and atrial fibrillation (RIVER trial) proved it to be non-inferior to warfarin. The role of newer oral anticoagulants in patients with prosthetic valves is the current focus of research. With large number undergoing transcutaneous aortic valve implantation (TAVI) which is a bioprosthetic device, deciding what constitutes the optimal anticoagulant for them has become an emerging clinical challenge.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Ansell J, Hirsh J, Hylek E, et al. American College of Chest Physicians Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (suppl 6):160S–198S.
3. Lengyel M. SPORTIF-II: Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic AF? Orv Hetil 2004; 145: 2619-21
4. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107:1692–711
5. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S-629S
6. Writing Committee Members- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77:450-500
7. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Jul 11; 70(2):252-289. Doi: 10.1016/j.jacc.2017.03.011. Pub 2017 Mar 15. PMID: 28315732.
8. Huang JT, Chan YH, Wu VC, et al. Analysis of Anticoagulation Therapy and Anticoagulation- Related Outcomes among Asian Patients after Mechanical Valve Replacement. JAMA Netw Open. 2022; 5(2):e2146026.
9. Edmunds LH Jr. Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987; 44:430‑45.
10. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348(9025):423-8.
11. Ageno W, Garcia D, Aguilar MI, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol 2009; 84:584–8?
12. Institute of Medicine (US) Roundtable on Translating Genomic-Based Research for Health. The Value of Genetic and Genomic Technologies: Workshop Summary. Washington (DC): National Academies Press (US); 2010. 3, Pharmacogenomic Testing to Guide Warfarin Dosing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK52750/
13. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635‑41
14. Singh V, Garg A, Singh G, Kapoor S, Ralhan S, et al. Analysis of anti-coagulation therapy related complications in patients with prosthetic valves: Our experience. Ann Card anaesth 2022; 25: 67-72
15. Dhanya PS, Nidheesh C, Kuriakose KM, Puthiyaveetil N. Pattern of oral anticoagulant use following prosthetic heart valve replacement: A prospective observational study. Indian J Thorac Cardiovasc Surg 2011; 27:119‑24.
16. Lung B, Rodes-Cabau J. The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. Eur Heart J. 2014; 35:2942-9
17. Chebrolu P, Patil S, Laux TS, et al. Quality of anticoagulation with warfarin in rural Chhattisgarh, India. Indian J Med Res. 2020; 152(3):303-307
18. Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: An American College of Chest Physicians clinical practice guideline. Chest 2022: 162 (5): e207-e243
19. Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart 2006; 92:1520–1525
20. Pasvol T, Macgregor E, Rait G et al. Time trends in contraceptive prescribing in UK primary care 2000–2018: a repeated cross-sectional study. BMJ Sex Reprod Health 2022; 48 (1): 193–198
21. D'Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J 2017; 38(19):1509-1516
22. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160:191–6.
23. Lester et al. British Society for Hematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves. Br J Haematol 2023; 202:465–478
24. Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020; 396(10264):1767-1776
25. Eikenboom JW, Connolly SJ, Brueckmann M, et al-RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369:1206014
26. Guimaraes HP, Lopes RD, Pedro GM, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020; 383:2117-2126
27. Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022; 387:978-988
28. Kalra R, Patel N, Doshi R, et al. Evaluation of the Incidence of New-Onset Atrial Fibrillation After Aortic Valve Replacement. JAMA Intern Med 2019; 179(8):1122-1130
29. Dangas GD, Tijssen JGP, Wöhrle J, et al.; GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382:120-9
30. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020; 382:1696-707
31. Rowe AS, Dietrich S, Hamilton LA. Analysis of anticoagulation reversal survey (ARES). Hosp Pract (1995). 2020; 48(3):123-127
32. Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant). Anthos-Press-Release-final.pdf (anthostherapeutics.com) dated 18th September, 2023